1. American Cancer Society (2009). Cancer Facts & Figures 2009. Atlanta: American Cancer Society.
2. Saphner, T., Tormey, D. C., & Gray, R. (1996). Annual hazard rates of recurrence for breast cancer after primary therapy. Journal of Clinical Oncology, 14(10), 2738–2746.
3. Houghton, J. (2006). Initial adjuvant therapy with anastrozole (A) reduces rates of early breast cancer recurrence and adverse events compared with tamoxifen (T) - data reported on behalf of the ATAC (‘Arimidex’, tamoxifen, alone or in Combination) Trialists’ group. Annals of Oncology, 17(Suppl. 9), 94. Abstract 243PD.
4. Mansell, J., Monypenny, I. J., Skene, A. I., Abram, P., Carpenter, R., Gattuso, J. M., et al. (2009). Patterns and predictors of early recurrence in postmenopausal women with estrogen receptor-positive early breast cancer. Breast Cancer Research and Treatment, 117(1), 91–98.
5. Lamerato, L., Havstad, S., Gandhi, S., Jones, D., & Chlebowski, R. (2005). Breast cancer recurrence and related mortality in US patients with early breast cancer. Journal of Clinical Oncology, 23(16S), 62s. Abstract 738.